Virpax Pharmaceuticals (Nasdaq:VRPX) announced today that it will pursue a direct to over-the-counter (OTC) regular pathway for Epoladerm. Berwyn, Pennsylvania–based Virpax designed the Epoladerm investigational pre-filled topical spray analgesic product for the non-addictive management of chronic pain associated with osteoarthritis (OA) of the knee. Get the full story at our sister site, Drug Delivery Business News.
Pain Management
Vivera adds two industry veterans to its technology advisory board
Vivera announced today that it added Robert Massoudi and Bryan Hughes to its technology advisory board. Massoudi and Hughes will support Newport Beach, California-based Vivera in its product and software development initiatives while forging strategic partnerships for Zicoh, the company’s electronic dose-controlled medication delivery system designed to improve prescription drug adherence, including medications with a higher […]
InfuSystem, Ventis Pharma enter pain management marketing deal
InfuSystem (NSYE:INFU) announced today that it entered into a national sales and marketing agreement with Ventis Pharma. Rochester Hills, Michigan-based InfuSystem’s partnership with Ventis will focus on sales and marketing for the latter’s patented Endura-Kit brand of Enduracaine, a local anesthetic compound. The kit consists of three non-opioid drugs: tetracaine, lidocaine and epinephrine. Get the full […]
Early study supports experimental hydrogel injection for chronic low back pain
A study demonstrated that an experimental hydrogel formulation was safe and effective in substantially relieving chronic low back pain. Research presented at the Society of Interventional Radiology Annual Scientific Meeting in Boston supported the hydrogel, which was injected into spinal discs in an effort to relieve chronic low back pain caused by degenerative disc disease […]
NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia
NeuroMetrix (Nasdaq:NURO) announced today that it received FDA de novo authorization for its Quell neuromodulation device. Quell received the authorization as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. Quell garnered FDA breakthrough device designation to treat fibromyalgia in July 2021. Much like when it received the breakthrough nod, […]
Avanos rises as Q1 earnings match Wall Street projections
Avanos Medical (NYSE:AVNS) shares ticked up today on first-quarter results that just about matched the consensus forecast. The Alpharetta, Georgia–based pain management and chronic care device company posted profits of $5.8 million, or 12¢ per share, on sales of $197.4 million for the three months ended March 31, 2022, for a bottom-line gain from losses […]
Stevanato Group, Bexson expand partnership for wearable drug delivery device
Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration. Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and post-traumatic stress disorder […]
Ear-puffing device for migraine treatment wins FDA breakthrough designation
A handheld device that treats migraine attacks with puffs of air in a patient’s ears has been designated a breakthrough device by the FDA. Tempe, Arizona-based Nocira said it is the first company to announce breakthrough device designation for treating migraine attacks in both chronic and non-chronic migraine patients ages 18 and up. The device […]
NeuroMetrix revenues rise in Q1
NeuroMetrix (Nasdaq:NURO) shares dipped today on first-quarter results that saw losses despite year-over-year revenue growth. The Woburn, Massachusetts–based company posted losses of $958,562, or 14¢ per share, on sales of $2.3 million for the three months ended March 31, 2022, for a bottom-line slide deeper into the red on sales growth of 6.8%. NeuroMetrix’s biggest […]
Abbott launches upgraded digital health app for neurostimulation
Abbott (NYSE:ABT) announced today that it launched an upgraded version of its NeuroSphere myPath digital health app. The Abbott Park, Illinois-based company designed the upgraded app with enhanced functionality to help doctors more closely track their patients as they trial Abbott neurostimulation devices to address their chronic pain. According to a news release, Abbott’s digital […]
Medtronic survey says pandemic has negatively impacted those with chronic back and leg pain
Medtronic (NYSE:MDT) today released data from a survey demonstrating several struggles for those with chronic pain during the COVID-19 pandemic. The survey, commissioned by Medtronic and conducted by public opinion research firm The Harris Poll, found that 44% of current chronic back and leg pain sufferers experienced care delays during the COVID-19 pandemic despite 87% […]
